Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 11, 2009, Pages 2938-2940

  Honda, Takeshi ^a   Kubo, Shuku ^a   Masuda, Takeshi ^a   Arai, Masami ^a   Kobayashi, Yoshiyuki ^a   Yamashita, Makoto ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

CS 8958; Ester prodrug; Influenza; Long acting NA inhibitor; Zanamivir

Indexed keywords

ANTIVIRUS AGENT; CARBOXYLIC ACID; CS 8958; ESTER DERIVATIVE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS; MOUSE; NONHUMAN; THERAPY EFFECT;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIVIRAL AGENTS; ESTERS; INFLUENZAVIRUS A; INFLUENZAVIRUS B; MICE; NEURAMINIDASE; PRODRUGS; ZANAMIVIR;

MUS; ORTHOMYXOVIRIDAE;

EID: 65149099661     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.04.067     Document Type: Article

References (29)

1. Monto A.S., Iacuzio I.A., and LaMontague J.R. J. Infect. Dis. 176 (1997) 51
2. Glezen W.P. Epidemiol. Rev. 4 (1982) 25
3. Webster R.G., Reay P.A., and Laver W.G. Virology 164 (1988) 230
4. Babu, Y.S.; Chand, P.; Montgomery, J.A. PCT Int. Appl., WO9747194.
5. Babu Y.S., Chand P., Bantia S., Kotian P., Dehghani A., El-Kattan Y., Lin T.H., Hutchison T.L., Elliott A.J., Parker C.D., Ananth S.L., Horn L.L., Laver G.W., and Montgomery J.A. J. Med. Chem. 43 (2000) 3482
6. Maring, C. J; Giranda, V.L.; Kempf, D.J.; Stoll, V.S.; Sun, M.; Zhao, C; Gu, Y.C.; Hanessian, S.; Wang, G.T. PCT Int. Appl., WO0128996.
7. Smith P.W., Sollis S.L., Howes P.D., Cherry P.C., Starkey I.D., Cobley K.N., Weston H., Scicinski J., Merritt A., Whittington A., Wyatt P., Taylor N., Green D., Bethell R., Madar S., Fenton R.J., Morley P.J., Pateman T., and Beresford A. J. Med. Chem. 41 (1998) 787
8. Sollis S.L., Smith P.W., Howes P.D., Cherry P.C., and Bethell R.C. Bioorg. Med. Chem. Lett. 6 (1996) 1805
9. Wyatt P.G., Coomber B.A., Evans D.N., Jack T.I., Fulton H.E., Wonacott A.J., Colman P., and Varghese J. Bioorg. Med. Chem. Lett. 11 (2001) 669
10. Watson K.G., Cameron R., Fenton R.J., Gower D., Hamilton S., Jin B., Krippner G.Y., Luttick A., McConnell D., MacDonald S.J.F., Mason A.M., Nguyen V., Tucker S.P., and Wu W.-Y. Bioorg. Med. Chem. Lett. 14 (2004) 1589
11. MacDonald S.J.F., Cameron R., Demaine D.A., Fenton R.J., Foster G., Gower D., Hamblin J.N., Hamilton S., Hart G.J., Hill A.P., Inglis G.G.A., Jin B., Jones H.T., McConnell D.B., McKimm-Breschkin J., Mills G., Nguyen V., Owens I.J., Parry N., Shanahan S.E., Smith D., Watson K.G., Wu W.-Y., and Tucker S.P. J. Med. Chem. 48 (2005) 2964
12. von Itzstein M., Wu W.-Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Phan T.V., Smythe M.L., White H.F., Oliver S.W., Colman P.M., Varghese J.N., Ryan D.M., Woods J.M., Bethell R.C., Hotham V.J., Cameron J.M., and Penn C.R. Nature 363 (1993) 418
13. Ryan D.M., Ticehurst J., Dempsey M.H., and Penn C.R. Antimicrob. Agents Chemother. 38 (1994) 2270
14. Woods J.M., Bethell R.C., Coates J.A., Healy N., Hiscox S.A., Pearson B.A., Ryan D.M., Ticehurst J., Tilling J., Walcott S.M., and Penn C.R. Antimicrob. Agents Chemother. 37 (1993) 1473
15. Hayden F.G., Treanor J.J., Betts R.F., Lobo M., Esinhart J.D., and Hussey E.E. JAMA 275 (1996) 295
16. Williams M.A., Lew W., Liu H., Mendel D.B., Tai C.Y., Escarpe P.A., Laver W.G., Stevens R.C., and Kim C.U. Bioorg. Med. Chem. Lett. 14 (1997) 1837
17. Kim C.U., Lew W., Williams M.A., Liu H., Zhang L., Swaminathan S., Bischofberger N., Chen M.S., Mendel D.B., Tai C.Y., Laver W.G., and Stevens R.C. J. Am. Chem. Soc. 119 (1997) 681
18. Kim C.U., Lew W., Williams M.A., Wu H., Zhang L., Chen X., Escarpe P.A., Mendel D.B., Laver W.G., and Stevens R.C. J. Med. Chem. 41 (1998) 2451
19. Mendel D.B., Tai C.Y., Escarpe P.A., Li W., Sidwell R.W., Huffmann J.H., Sweet C., Jakeman K.J., Merson J., Lacy S.A., Lew W., Williams M.A., Zhang L., Chen X., Bischofberger N., and Kim C.U. Antimicrob. Agents Chemother. (1998) 640
20. Hay A.J. Semin. Virol. 3 (1992) 21
21. Honda T., Masuda T., Yoshida S., Arai M., Kobayashi Y., and Yamashita M. Bioorg. Med. Chem. Lett. 12 (2002) 1921
22. 50 (nM) sialidase inhibitory and plaque reduction activities of compounds were determined by previously reported methods. {A table is presented}
23. Compound 3 and Zanamivir were administered intranasally at doses of. 0.2 μmol/kg 4 h before and 4 h, 17 h after the infection in mice. Compound3 was more effective than Zanamivir (2/10 survived in the 3 treated infected group while there was no survivor in the case of Zanamivir at 20 days after infection).
24. Honda T., Masuda T., Yoshida S., Arai M., Kaneko S., and Yamashita M. Bioorg. Med. Chem. Lett. 12 (2002) 1925
25. Okazaki T., Suga A., Watanabe T., Kikuchi K., Kurihara H., Shibasaki M., Fujimori A., Inagaki O., and Yanagisawa I. Chem. Pharm. Bull 46 (1998) 287
26. {A table is presented}
27. Compounds 10a-10c were administered intranasally at doses of 0.3 μmol/kg 4 h before and 4 h, 17 h after the infection in mice. There was no survivor in the 10a, 10b, and 10c-treated infected groups at 20 days after infection.
28. Compounds 12d, 12e,12f, and Zanamivir were administered intranasally at doses of 0.3 μmol/kg 4 h before and 4 h, 17 h after the infection in mice. Their efficacies were found to be almost same as that of Zanamivir (there were no survivors in the 12d, 12e, 12f, and Zanamivir-treated infected groups at 9 days after infection).
29. Yamashita M., Tomozawa T., Kakuta M., Tokumitsu A., Nasu H., and Kubo S. Antimicrob. Agents Chemother. 53 (2009) 186